Open mobile menu
Model.SiteSettings!.GetInTouchLink!.Name Contact Us
Jroberts Jruaux Dpingstone 03 B012378 CROPPED
Insights

News

Stay up to date with news about Secerna and intellectual property topics.

LEQEMBI

A to Z: Drugs in Highlight: L is for LEQEMBI®

News A to Z Feature 19/02/2025

This series continues to explore the fascinating world of pharmaceuticals. LEQEMBI® (from Eisai GmbH) uses lecanemab for treating early Alzheimer’s disease in apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes.  It is particular for those patients with a clinical diagnosis of mild cognitive impairment and mild dementia. It is available as a 100 mg/mL injection for intravenous use.

Read more
LEQEMBI
News, A to Z Feature 19/02/2025

A to Z: Drugs in Highlight: L is for LEQEMBI®

Secerna Website Images 2025 (5)
Events, News 17/02/2025

Secerna LLP are presenting at NEPIC Pharma Connect 2025

Secerna Website Images 2025 (6)
Events, News 14/02/2025

Secerna attending Agri-Tech Expo North

KALYDECO
News, A to Z Feature 13/02/2025

A to Z: Drugs in Highlight: K is for KALYDECO®

Protect Your Global Brand Essential Trade Mark Services (1)
News 11/02/2025

Protect Your Global Brand: Essential Trade Mark Services

J Is For JANUVIA®  (1)
News, A to Z Feature 06/02/2025

A to Z: Drugs in Highlight: J is for JANUVIA®

EU FLAG Canva
Industry news, News 03/02/2025

UPC finds infringement by way of equivalence for the first time

IMBRUVICA
News, A to Z Feature 30/01/2025

A to Z: Drugs in Highlight: I is for IMBRUVICA®

Secerna Website Images 2025 (4)
Industry news, News 27/01/2025

Unlocking Faster Cancer Treatments: The Power of Project Orbis

1 2 3 4 5 6